Health Trials

Switch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine

ConditionsPatient SatisfactionPatient PreferenceQuality of LifeAcceptability of Health Care
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorPontificia Universidad Catolica de Chile

About this trial

This protocol will assess the level of satisfaction, acceptance of treatment and quality of life of patients with undetectable HIV who voluntarily change from oral to injectable antiretroviral treatment at 72 weeks of follow-up.

Eligibility criteria

Qualifiers

HIV-1 positive patients, on antiretroviral therapy

Older than 18 years of age at the time of signing the informed consent

Undetectable HIV viral load in the last 6 months

Willing to switch from oral to injectable therapy

Disqualifiers

Previous virological failure

Any evidence of primary resistance or the presence of any major known INI or NNRTI resistance-associated mutation by any historical resistance test result.

Patients with decompensated pathology (physical or mental) or active opportunistic infection at the time of admission

Concomitant use with: rifampin, carbamazepine, oxcarbazepine, phenytoin and phenobarbital or any contraindication to one of the drugs of the study

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Sponsors and collaborators

Pontificia Universidad Catolica de Chile

Lead sponsor

ViiV Healthcare

Collaborator

Source ClinicalTrials.gov